脈衝生物科學 PLSE 深 滬
等待開盤 02-10 09:30:00 美东时间
22.95
+2.200
+10.60%
華盛通- 最 高23.08
- 今 開21.33
- 成交量 89.57万股
- 最 低 20.3304
- 昨 收 20.75
- 總市值 15.55亿
- 52周最高 23.08
- 市盈率 靜 --
- 換手率 1.32%
- 52周最低 12.56
- 委 比 80.31%
- 總股本 6776.76万
- 歷史最高 45.82
- 量 比 1.34
- 振 幅 13.25%
- 歷史最低 1.18
- 每 手 1
- 風險率 1.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going With Pulse Biosciences Stock On Monday?
Pulse Biosciences stock rises after new study data showed strong early results for its heart treatment device, helping shares outperform a weak broader market.
02-09 22:18
美股周涨跌榜 | 光通信龙头Lumentum业绩炸裂！周内飙涨逾40%；创新药公司MANE上市股价即翻倍
光通信龙头Lumentum业绩炸裂！周内股价飙涨逾40%；创新药公司MANE上市即翻倍，聚焦脱发口服药物；德州仪器75亿美元收编芯科实验室>>
02-07 11:39
Reported Earlier, Pulse Biosciences Highlights nPulse Cardiac Catheter Ablation Study Achieving Durable AF Treatment Outcomes With Average Procedure Time Of 65 Minutes And Low SAE Rate
Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months
02-06 16:37
Pulse Biosciences gains FDA IDE for NANOPULSE-AF trial
An announcement from Pulse Biosciences ( ($PLSE) ) is now available. On Decembe...
2025-12-18 22:28
Pulse Biosciences Teams Up With MD Anderson To Test New Thyroid Cancer Treatment In FDA-Approved Study
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or
2025-12-09 20:10
Pulse Biosciences Updates Investors on Product Advancements
Pulse Biosciences ( ($PLSE) ) just unveiled an announcement. On November 13, 20...
2025-11-13 22:48
Pulse Biosciences Announces Enrollment Of First Patient In NANOCLAMP AF Study For Treatment Of Atrial Fibrillation
First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical ProcedurePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology
2025-10-24 19:01
Pulse Biosciences Reveals Promising Study Results
Pulse Biosciences ( ($PLSE) ) has provided an announcement. On October 10, 2025...
2025-10-10 21:28
Pulse Biosciences Announces Late-Breaking Clinical Study Results From nPulse Cardiac Surgical System First-In-Human Feasibility Study At 39th European Association For Cardio-Thoracic Surgery Annual Meeting
Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical SystemPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using
2025-10-10 19:02
Pulse Biosciences Begins First Study Using Nanosecond PFA Tech To Treat Benign Thyroid Nodules
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures
2025-09-02 19:05
